Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EPS (Weighted Average and Diluted) (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.87 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 101.33% to -$0.87 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.66 through Dec 2025, up 76.46% year-over-year, with the annual reading at -$2.65 for FY2025, 76.0% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.87 in Q4 2025 for Camp4 Therapeutics, down from -$0.55 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $65.46 in Q4 2024 to a low of -$30.18 in Q4 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$7.33 across 3 years, with a median of -$12.53 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 316.9% in 2024 and later plummeted 101.33% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$30.18 in 2023, then surged by 316.9% to $65.46 in 2024, then tumbled by 101.33% to -$0.87 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CAMP at -$0.87 in Q4 2025, -$0.55 in Q3 2025, and -$0.62 in Q2 2025.